Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

I will now turn the call over to Kate Roush, Vice President of Corporate Affairs and Investor Relations. Thank you, Operator, and good morning to everyone on the call. Earlier this morning, we issued a press release outlining our third quarter 2025 earnings update. Joining me today with prepared remarks are Dr. Paul Bono, President and Chief Executive Officer, and Kyle Moran, Chief Financial Officer. Dr. Chris Wright, Chief Medical Officer. Dr. Eric Engelson, Chief Scientific Officer, and Dr. Chandra Varghese, Chief Technology Officer, will be available for questions following the prepared remarks. The press release issued this morning is available in the investor section of our website, www.wavelifesciences.com. Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause their actual results to differ materially from those described in these forward-looking statements. The factors that could cause our actual results to differ are discussed in the press release issued today and in our SEC filings. We undertake no obligation to update or revise any forward-looking statement for any reason. I'd now like to turn the call over to Paul. Thanks, Kate, and good morning to everyone joining us on today's call. I would like to first thank those of you who were able to join us for our 2025 Research Day on October 29th, where we shared the first-ever demonstration of activity reductions in a clinical trial. Notably, with a single dose of WVE-007, our inhibited GalNec siRNA, we were excited to show highly significant and durable human activity reductions that exceeded levels needed in preclinical models to drive meaningful weight l...